‘Devastating': 10 Harvard researchers detail ‘essential' work set to be cut by Trump
From a fruit fly database, to developing 'organ chip' technology, to the study of deer mice — all of it could have serious implications for understanding, finding cures for or helping alleviate human diseases, Harvard University researchers say.
And yet, those explorations are among thousands of federal research grants and billions of dollars the Trump administration has cut in recent months.
In court filings, Harvard — global research mecca — claims it is being targeted by a 'government vendetta,' as President Donald Trump strips much of its federal money and contracts in the name of addressing antisemitism.
But what research is actually being done at Harvard? And does it matter if it gets cut?
MassLive is profiling 10 researchers, using interviews and court affidavits, whose work will be entirely stopped or severely affected by federal government cuts.
A federal judge on Monday ordered the Trump administration to restore 367 National Institutes of Health grants as part of two lawsuits, but the order doesn't apply to a broad swath of grants, including the huge numbers at Harvard.
There have been 2,282 NIH grants terminated nationally, amounting to nearly $3.8 billion of lost funding as of June 4, according to the Association of American Medical Colleges.
The funding cuts at Harvard have led to layoffs at the Harvard T. H. Chan School of Public Health, as every one of its direct federal grants has been terminated. The school has even taken to social media to ask for donations.
Read more: As federal funding cuts hit Harvard, a private investment firm and other donors step up
Harvard announced it has committed $250 million of 'central funding' to support research affected by suspended and canceled federal grants.
However, even with the boost of funding from the university, research is threatened and could be significantly affected without federal money, according to Harvard researchers.
Overwhelmingly, researchers told MassLive that while Harvard may be the facilitator for the work they're doing, it's not 'Harvard research' — rather, it's research for the world. They also argued that the cuts are wasteful and costly because they stop research prematurely, making all funding that came before it nearly useless.
Position: Genome database coordinator, a staff scientist position in the Department of Molecular and Cellular Biology at Harvard University
Victoria Jenkins extracts, interprets and archives data to keep FlyBase, the world's central repository for fruit fly research, running.
The website is a free treasure trove of 32 years' worth of data for scientists across the world to access. Fruit flies are genetically similar to humans — nearly 70% — making them cheap and accessible test subjects to work with. The site contains information about every fruit fly gene and genome.
'We're the Wikipedia of fruit fly research,' Jenkins said in an interview. 'There really isn't a second version of what we do. We are the one resource for this information.'
In May, FlyBase's grant funding from the National Institutes of Health was terminated. Now, researchers are searching for other forms of funding to, at the very least, preserve the website as is.
Jenkins said Alzheimer's, Parkinson's, addiction, traumatic brain injuries and birth defects have all been modeled in flies as researchers work to make scientific breakthroughs. Six Nobel Prize projects have been awarded to fruit fly-related research.
And the results are all found on FlyBase, which is a multi-university partnership between Harvard, Indiana University, University of New Mexico and the University of Cambridge in the United Kingdom.
'Every fly researcher around the world relies on us for historical data and everything new that gets produced,' Jenkins said.
Position: Professor of Organismic and Evolutionary Biology at Harvard University
When Bence Ölveczky came to the U.S. at the age of 28 from Hungary, it was the first place where he didn't feel like a foreigner.
'This is a unique country because it's a country of immigrants. And that's why I felt at home because nobody cared,' he told MassLive.
Now it feels like the climate is changing. He isn't able to encourage students to come to the university.
At the same time, he is piecing together funding for his research after the funding terminations. He is working to understand how rats learn, which will inform rehabilitation, helping people who have had strokes or have Parkinson's.
'It's an inspiration to me that we could help in the treatment of these,' he said.
Using 'rainy day' funds he received a decade ago from when he was promoted, he hasn't had to lay off staff yet — but these funds will dry up within the year, he said. In addition to potential layoffs, around 100 rats would also have to be euthanized because the lab won't have the funding to keep going.
Position: Professor of computational biology and bioinformatics at the Harvard T.H. Chan School of Public Health. He is also the chair of the Department of Biostatistics.
For over three decades, John Quakenbush has been working in biomedical research, investigating the mechanisms that cause healthy people — and ultimately their cells — to become diseased.
Despite his decades of experience, he said he is looking at leaving the United States.
'I stand behind Harvard in its decision to fight for its First Amendment rights,' Quakenbush said in an interview. 'But I'm looking, at this point in my career, at potentially two years with almost no external research funding — maybe longer. And, as you get to that point, and you're not doing research anymore, picking back up and starting up again becomes more difficult. Even securing federal research grants becomes difficult.'
Part of Quakenbush's research is attempting to uncover a 'fundamentally important but understudied problem in health.' He is both unpacking how sex and age interact to influence disease risk and how diseases differ between biological males and females.
Without the funding, he doesn't know what'll happen next, but said sex is important to understand how nearly every disease has different ways it manifests or responds to therapy.
" The political agenda that we don't want to acknowledge different genders or we don't even want to go beyond individual sexes is sort of ridiculous because disease strikes us all right? Independent of who we voted for, who we love, what church we go to or don't go to," Quakenbush said.
Position: Associate professor of social and behavioral sciences at the Harvard T.H. Chan School of Public Health
When describing the affects of federal research cuts in a recent court filing, Shoba Ramanadhan used the word 'devastating' multiple times.
Four of her federal grants have been terminated or ended early. They included research related to the impact of climate change-caused heat stress and cancer-focused outreach to immigrants, refugees and minority communities.
'I work closely with communities that have been subject to discrimination in the United States, such as racial and ethnic minorities and LGBTQ+ groups,' Ramanadhan wrote in her court affidavit. 'Given historical and current abuses of power, these communities are understandably skeptical of scientists and academic researchers. It can take us anywhere from 5 to 15 years to build the requisite trust and relationships with a community and partner on research.'
Ramanadhan warned that if her projects can't be completed, 'people in the communities we serve will not be supported to engage in cancer prevention activities, such as breast cancer screening or vaccination against HPV.'
She also expressed concerns that an entire cohort of faculty working toward tenure, herself included, could lose the opportunity to achieve it because of federal research cuts.
Kelsey Tyssowski
Position: Postdoctoral Research Associate in the Departments of Organismic & Evolutionary Biology and Molecular & Cellular Biology at Harvard University.
Without funding for Kelsey Tyssowski's work, she may have to leave academic science entirely.
Her pathway to getting a tenure-track job has been halted by federal funding cuts. Her research only has funding until the end of the month — then it is up to tenure faculty to determine if she will have any left.
A canceled grant from the National Institutes of Health was supposed to cover her salary through March 2026 and the first three years of research in her own lab.
'I have to get a job this year. And this year it's going to be very hard to get a tenure track faculty job because there's hiring freezes everywhere,' Tyssowski said. 'If I can't stay in this job here, I almost certainly have to leave academia.'
Tyssowski's research involves skilled movement, complex learned movements that can be reproduced accurately and efficiently and take entire body coordination to do, like climbing.
She is pioneering a new way to study skilled movement through deer mice — whose skilled movement might have evolved in a way that humans and primates have.
This could provide significant understanding on how human brains engage in skilled movement, and ultimately, in treating diseases such as ALS, where skilled movement is the first thing to go.
If she leaves academia, the work that she has been doing is at risk of completely vanishing.
'No one will do this research. I won't do this research. It will just go away,' she said.
Position: Social epidemiologist and director of the Social Policies for Health Equity Research Center at the Harvard T.H. Chan School of Public Health
Rita Hamad has spent nearly 20 years studying the effects of social policies on health, poverty and education. Specifically, how policies can have the power to lift up marginalized communities and improve their health, or make it worse.
It is an 'unbelievably devastating time for science in general, but particularly for us that study health equity,' she said in an interview.
Hamad has seen three of her NIH grants canceled. One was used to study how neighborhood socioeconomic factors affect risk for Alzheimer's and dementia.
'We need to know what about communities we can intervene in to improve these risk factors,' she said. 'If you don't have that information, you're not preventing any cases of dementia.'
A second grant was used to examine the effects of school segregation on the cardiovascular health of youth and young adults. Research so far has shown that children who experience school segregation have a higher risk of worse health in childhood and years later, she said.
'All of that research is grinding to a halt, doing a disservice to people of all backgrounds,' Hamad said.
'Clinging to whatever I can,' Hamad said she's trying to remain hopeful that her grant funding will be restored and the damage 'reversible.'
'We're not just here to get a paycheck,' she said. 'We're here to make the world a better and healthier place.'
Position: Founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University
With Donald Ingber's ongoing work, the U.S. had a better chance at exploring Mars. But the federal government has instructed him to cease his projects.
Ingber and his team have been working to develop human 'organ chip' technology — 'tiny, complex, three-dimensional models with hollow channels lined by different types of cells and tissues that recapitulate the structure and function of human organs,' he wrote in a court affidavit.
One of Ingber's projects was using the organ chip to study the effects of microgravity and radiation on astronauts during spaceflight. Ingber was developing specialized bone marrow chips incorporating cells from individual astronauts.
The specialized chips were scheduled to fly aboard the Artemis II mission to the moon, scheduled for early 2026, alongside the astronauts who donated the cells, Ignber said.
'This work is critical to our ultimate ability to explore Mars, because protecting astronauts from radiation toxicity remains a major barrier to the long-distance space travel necessary to explore the solar system,' he continued.
The second project using the organ chip technology was studying how the human lung, intestine, bone marrow and lymph node respond to radiation, with the goal of identifying drugs 'that can mitigate the effects of that radiation.'
Ingber said the work was important to improve public safety, 'as the country ramps up nuclear power production to support the energy-intensive artificial intelligence industry.'
'These countermeasures also would be available in the case of a nuclear attack and to alleviate toxic side effects in cancer patients who receive radiation therapy,' he said.
Position: Professor of epidemiology and nutrition at the Harvard T.H. Chan School of Public Health
Kept frozen by liquid nitrogen inside laboratories at Harvard University are more than 1.5 million biospecimens that have mere 'weeks' left until they spoil. Soon, there won't be enough money left to keep the freezers running.
The nearly 50 years of collected human feces, urine, blood, tumors and even toenail clippings could have consequential implications for the future health of Americans, and yet, they're at risk of being lost if funding slashed by the Trump administration isn't restored.
Read more: Trump cuts threaten 'irreplaceable' Harvard stockpile of human feces, urine
The mother lode collection housed at Harvard has supported generations-long chronic disease risk studies that have fundamentally shaped significant scientific and medical advancements.
The studies have led to major breakthroughs, including links between cigarettes and cardiovascular disease and alcohol consumption and breast cancer. The research also uncovered the dangers of trans fats, which the U.S. has now largely restricted.
The biological samples collected during the studies are 'irreplaceable,' according to Walter Willett, one of the most sought-after nutritionists internationally.
And some of the study participants could even die before the next check-in period, he said.
'No other institution in the world has this data,' Willett wrote in a May 30 court affidavit detailing the effects of federal funding cuts on his research.
Position: Senior lecturer in the Department of Biostatistics and Epidemiology at the Harvard T.H. Chan School of Public Health
Personally, Paige Williams, a Harvard faculty member of 34 years, stands to lose 90% of her salary due to revocations of NIH grants. Professionally, she fears the downstream effects on clinical research in the future, particularly when it comes to community trust.
She cited some of her study participants — women living with HIV — who have already expressed feeling 'betrayed' when study activities abruptly stopped in May.
'As HIV researchers, we rely on the willingness of our study participants to share openly some of the most vulnerable and challenging aspects of their lives,' Williams wrote in a court filing. 'Our work thus depends on a foundation of trust between us and the participants we work with…'
Williams primarily studies health outcomes in pregnant women and their children, and much of her work is HIV-centered. One of her terminated grants was a 20-year study evaluating the effects of anti-retroviral treatment for mothers with HIV and their children — currently in its final year.
Because of the grant stoppage, her research team was essentially unable to procedurally finish two decades of work. In addition, they're slated to lose data they've collected, Williams wrote.
'Losing the data arising from such studies would be devastating for the entire scientific community and for the many Americans whose lives would be forever improved by scientific breakthroughs,' she said.
Position: Professor of Health Economics and Policy in the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health & interim department chair.
Meredith Rosenthal's research focuses on a tool to lower medication alternatives to help reduce out-of-pocket costs for patients and increase medication adherence.
She is aiming to understand how things may change based on people's socioeconomic statuses and geographic locations.
Around 60% of Rosenthal's salary comes from research grants. One of her grants provides almost $2.5 million over three and a half years, and she has one year left. Her grant was canceled on May 15, according to court documents.
'I firmly believe that equity is an essential value in health policy. I have dedicated my career to improving health and affordability for everyone, both through my research and by overseeing the school's Office of Diversity and Inclusion (from 2013-2018) to improve diversity, equity and inclusion of those who work in the industry and on our campus,' she said.
'I worry that the Trump administration will label my focus on equitable access to healthcare as an 'ideologically capture' DEI program and demand that the school 'shutter' the program, particularly because of my former diversity-related administrative role, but because of the vagueness of the Demand Letters, I cannot be sure,' she said.
Federal judge halts Trump's plans to keep Harvard from enrolling foreign students
Harvard researcher's work gives 'hope' for Parkinson's. But the feds cut his funding
These US colleges are among the top 100 best global universities, US News says
'Far reaching consequences' — UMass Amherst sounds the alarm amid federal uncertainty
MIT joins group of universities suing the DOD over funding cuts
Read the original article on MassLive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
A new weight-loss treatment that can be administered as either a weekly injection or a daily pill has shown promising results in early-stage trials, according to a new study. In one of the trials, 125 adults were assigned to weekly injections of amycretin. Those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost 15 per cent of their body weight over a longer 68 week period. Another trial enrolled 144 adults to test the pill version of amycretin. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. While jabs like Ozempic, Wegovy and Mounjaro only target the body's GLP-1 receptors, amycretin targets them as well as the amylin receptors, which help regulate blood glucose levels and appetite. The drug helps to prevent overeating and promote feelings of satiety. The findings were published in The Lancet and presented this week at the American Diabetes Association's Scientific Sessions in Chicago. Researchers also reported that the drug appeared to improve participants' blood sugar control, an important marker for those at risk of developing Type 2 diabetes. Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers. Pill formulations may simplify prescribing and make long-term weight-loss support easier to scale up. Unlike drugs like Ozempic, amycretin tablets would not need to be refrigerated and do not require syringes. However, amycretin remains in the early stages of clinical testing and that larger trials will be required to fully establish its safety and efficacy. Both forms of the drug were also associated with improvements in blood sugar levels. Patients did report side effects, including nausea and vomiting, but researchers said that they tended to resolve as the treatment progressed.
Yahoo
an hour ago
- Yahoo
DARPA smashes wireless power record, beaming energy more than 5 miles away — and uses it to make popcorn
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. military has set a new record for wireless power transmission, beaming a laser carrying more than 800 watts of power across a distance of 5.3 miles (8.6 kilometers). The test, performed by the U.S. military's Defense Advanced Research Projects Agency (DARPA) as part of its Persistent Optical Wireless Energy Relay (POWER) program, is a key step toward unlocking the near-instant beaming of power. It also smashes previous records set by the POWER program, which previously beamed 230 watts across 1 mile (1.7 km) for 25 seconds, and a smaller, undisclosed amount of power as far as 2.3 miles (3.7 km). "It is beyond a doubt that we absolutely obliterated all previously reported optical power beaming demonstrations for power and distance," Paul Jaffe, the POWER program manager, said in a statement. The concept of wireless power transmission (WPT) has been a popular goal since the days of Nikola Tesla, who in 1901 began constructing the Wardenclyffe Tower on Long Island, New York — a 187-foot (57 meters) structure intended to be the first node in a "World Wireless System" that would beam power around the globe. Yet technical challenges meant that funding for the project, initially provided by the financier J.P. Morgan, dried up, leaving Tesla's vision unrealized. Related: NASA's 1st successful 2-way laser experiment is a giant leap for moon and Mars communications Nonetheless, interest in the concept has recently increased, both for military applications and space-based solar power, a nascent technology that would collect and transmit energy from sunlight in space, where it is 10 times more intense than at Earth's surface. Energy is essential for military operations, and getting that energy to the battlefields and disaster areas where it's needed is slow, risky, and resource intensive, often using up a lot of fuel, DARPA representatives wrote in the statement. RELATED STORIES —World's most powerful X-ray laser set for massive upgrade that will help us better understand the atomic world —DARPA's military-grade 'quantum laser' will use entangled photons to outshine conventional laser beams—Scientists uncover the secret to building Star Wars-style laser weapons — but don't worry, we won't have a Death Star anytime soon "These tests, referred to as PRAD (POWER Receiver Array Demo), mark an important step toward the POWER program's long-term goal of being able to instantly beam power from a location where it can be easily generated to wherever it's needed," the agency added. In the latest experiment, conducted at the U.S. Army's White Sands Missile Range in New Mexico, the power was beamed over the 5.3-mile distance in a 30-second pulse. The laser beam arrived at the receiver before passing through a small aperture, bouncing off a parabolic mirror onto solar cells within. The pulse was transmitted with an approximate 20% efficiency, and some of the power it transmitted was used to make popcorn. The researchers have bigger ambitions for the system's use in the field, however, suggesting that it could be used to power unmanned aerial vehicles (UAVs). They will now move on to testing power beaming both across multiple connected relays and vertically, where the atmosphere is thinner and transmission more efficient.
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
